• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket

    10/2/23 8:11:18 AM ET
    $ACAQ
    $AWIN
    $BITF
    $BNOX
    Blank Checks
    Finance
    Aerospace
    Industrials
    Get the next $ACAQ alert in real time by email

    Gainers

    AERWINS Technologies Inc. (NASDAQ:AWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies is considering strategic alternatives for non-core operations including, not limited to possible sale/other disposition of assets.

    RVL Pharmaceuticals plc (NASDAQ:RVLP) shares rose 24.5% to $0.1078 in pre-market trading after gaining over 10% on Friday.

    Better Choice Company Inc. (NYSE:BTTR) shares gained 21.4% to $0.1505 in pre-market trading after gaining 5% on Friday.

    Bionomics Limited (NASDAQ:BNOX) shares rose 21.1% to $3.27 in pre-market trading after falling 20% on Friday.

    Athena Consumer Acquisition Corp. (NASDAQ:ACAQ) shares surged 20.4% to $8.98 in pre-market trading after falling 20% on Friday.

    EMCORE Corporation (NASDAQ:EMKR) rose 19.7% to $0.5691 in pre-market trading after falling 5% on Friday.

    Syndax Pharmaceuticals, Inc.. (NASDAQ:SNDX) gained 13.6% to $16.50 in pre-market trading. Syndax will share topline results from the pivotal AUGMENT-101 trial in patients with relapsed/refractory KMT2Ar acute leukemia on Oct. 2, 2023.

    Bitfarms Ltd. (NASDAQ:BITF) shares climbed 13.1% to $1.21 in pre-market trading.

    Femasys Inc. (NASDAQ:FEMY) rose 11.1% to $3.31 in pre-market trading. Femasys shares jumped 46% on Friday after HC Wainwright maintained a Buy rating on the stock and raised its price target from $5 to $13.

    Oragenics, Inc. (NYSE:OGEN) shares jumped 10.4% to $3.28 in pre-market trading after the company entered into agreement with Lantern Bioworks for replacement-therapy assets.

    Losers

    SmileDirectClub, Inc. (NASDAQ:SDC) fell 64.1% to $0.1489 in pre-market trading. SmileDirectClub filed for bankruptcy just a few years after its remarkable $1.35 billion IPO.

    Intelligent Bio Solutions Inc. (NASDAQ:INBS) fell 23.8% to $0.80 in pre-market trading after declining 7% on Friday.

    Context Therapeutics Inc. (NASDAQ:CNTX) shares fell 15.8% to $1.27 in pre-market trading after jumping around 19% on Friday.

    Nexalin Technology, Inc. (NASDAQ:NXL) fell 14.7% to $0.3752 in pre-market trading. On Sept. 21, 2023, Marilyn Elson submitted her resignation as CFO Of Nexalin Technology.

    ReShape Lifesciences Inc. (NASDAQ:RSLS) shares fell 14.2% to $0.2901 in pre-market trading after declining 23% on Friday. ReShape Lifesciences reported pricing of $3.0 million public offering.

    Brooge Energy Limited (NASDAQ:BROG) fell 9.8% to $5.02 in pre-market trading. Brooge Energy said revenue jumped 122% year-over-year to $62.9 million for the first six months ending June 30, 2023.

    Danaher Corporation (NYSE:DHR) shares fell 9.6% to $224.32 in pre-market trading. Danaher said it completed separation of Veralto Corporation.

    Siyata Mobile Inc. (NASDAQ:SYTA) fell 9.6% to $2.55 in pre-market trading.

    Grom Social Enterprises Inc (NASDAQ:GROM) fell 8% to $1.26 in pre-market trading. Grom Social recently priced a $3 million offering.

    Bolt Biotherapeutics Inc (NASDAQ:BOLT) fell 7.7% to $0.96 in pre-market. The FDA recently granted Orphan Drug Designation for Bolt Biotherapeutics' BDC-1001 for gastric cancer, including gastroesophageal junction cancer.

    Now Read This: Nio, Li Auto And 3 Stocks To Watch Heading Into Monday

    Get the next $ACAQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAQ
    $AWIN
    $BITF
    $BNOX

    CompanyDatePrice TargetRatingAnalyst
    Bitfarms Ltd.
    $BITF
    1/27/2026$3.00Outperform → Mkt Perform
    Keefe Bruyette
    Danaher Corporation
    $DHR
    12/9/2025$265.00Buy
    Goldman
    Danaher Corporation
    $DHR
    12/2/2025$270.00Overweight
    Morgan Stanley
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    Bolt Biotherapeutics Inc.
    $BOLT
    10/20/2025$7.00Buy
    H.C. Wainwright
    Syndax Pharmaceuticals Inc.
    $SNDX
    10/16/2025$40.00Buy
    H.C. Wainwright
    Danaher Corporation
    $DHR
    10/8/2025$220.00Buy → Neutral
    Rothschild & Co Redburn
    Context Therapeutics Inc.
    $CNTX
    9/18/2025$5.00Buy
    Guggenheim
    More analyst ratings

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    SEC Filings

    View All

    SEC Form 6-K filed by Bitfarms Ltd.

    6-K - Bitfarms Ltd (0001812477) (Filer)

    3/9/26 3:34:08 PM ET
    $BITF
    Finance: Consumer Services
    Finance

    SEC Form 6-K filed by Bitfarms Ltd.

    6-K - Bitfarms Ltd (0001812477) (Filer)

    3/6/26 5:00:06 PM ET
    $BITF
    Finance: Consumer Services
    Finance

    SEC Form 6-K filed by Bitfarms Ltd.

    6-K - Bitfarms Ltd (0001812477) (Filer)

    3/5/26 5:20:47 PM ET
    $BITF
    Finance: Consumer Services
    Finance

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bitfarms downgraded by Keefe Bruyette with a new price target

    Keefe Bruyette downgraded Bitfarms from Outperform to Mkt Perform and set a new price target of $3.00

    1/27/26 8:40:33 AM ET
    $BITF
    Finance: Consumer Services
    Finance

    Goldman initiated coverage on Danaher with a new price target

    Goldman initiated coverage of Danaher with a rating of Buy and set a new price target of $265.00

    12/9/25 8:43:56 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Morgan Stanley initiated coverage on Danaher with a new price target

    Morgan Stanley initiated coverage of Danaher with a rating of Overweight and set a new price target of $270.00

    12/2/25 8:25:25 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

    -- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ATLANTA, March 10, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the initiation of patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc. This milestone follows U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to advance the study based on positive clinical data generated in its

    3/10/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

    All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sitesPotential first and only pharmacological treatment for the most prominent neurological condition without an FDA-approved therapeutic SARASOTA, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it has received final Human Research Ethics Committee (HREC) approval in Australia to commence its Phase IIa clinical trial evaluating its lead drug candidate, ONP-002, for the treatment of concussion also known as mi

    3/10/26 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bitfarms Expands Leadership Team with Seasoned U.S. Industry Experts to Support HPC/AI Infrastructure Development

    TORONTO and NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX:BITF), a North American digital infrastructure and energy company, today announced a series of strategic hires across its infrastructure and corporate teams. These additions bring deep expertise in power development, large‑scale construction, permitting, and corporate scaling as Bitfarms accelerates build‑outs across its portfolio. "We are excited to welcome Tara, Michael, Christopher, Paul, Kevin, and Tom to our leadership team," said CEO Ben Gagnon. "As we continue toward U.S. domiciliation and advance our sites, building a seasoned domestic leadership bench is essential. Our recent hires bring substantia

    3/9/26 7:05:00 AM ET
    $BITF
    Finance: Consumer Services
    Finance

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Riley Christopher Paul was granted 6,172 shares and covered exercise/tax liability with 1,115 shares, increasing direct ownership by 33% to 20,400 units (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    3/3/26 7:52:02 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SVP-Chief Legal Officer Leiken Jonathan was granted 2,374 shares, increasing direct ownership by 23% to 12,546 units (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    3/3/26 7:52:26 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Executive Vice President Mcgrew Matthew was granted 5,935 shares, increasing direct ownership by 28% to 26,825 units (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    3/3/26 7:52:22 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CEO and CFO Quinn William P. bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 6% to 2,313 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    2/4/26 4:32:38 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senior VP, Finance and PAO Nemec Sarah bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 10% to 1,415 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    2/4/26 4:32:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senior VP, Finance and PAO Nemec Sarah was granted 23,000 shares and bought $686 worth of shares (125 units at $5.49), increasing direct ownership by 2,827% to 23,943 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    10/24/25 7:19:22 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REVUFORJ issued to SYNDAX PHARMACEUTICALS INC

    Submission status for SYNDAX PHARMACEUTICALS INC's drug REVUFORJ (ORIG-1) with active ingredient REVUMENIB has changed to 'Approval' on 11/15/2024. Application Category: NDA, Application Number: 218944, Application Classification: Type 1 - New Molecular Entity

    11/18/24 9:22:42 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    Leadership Updates

    Live Leadership Updates

    View All

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Bitfarms Announces Board Chair Transition in Anticipation of U.S. Redomiciliation

    TORONTO, Ontario and NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Bitfarms Ltd. (NASDAQ/TSX:BITF) ("Bitfarms" or the "Company"), a North American energy and digital infrastructure company, today announced that Edie Hofmeister has been appointed as Chair of the Board of Bitfarms. This appointment supports Bitfarms' previously announced strategy of redomiciling to the United States. Ms. Hofmeister succeeds Brian Howlett who has served as Director since 2020, and Chairman since 2024. Mr. Howlett will continue to serve as an Independent Director. Ms. Hofmeister brings over two decades of extensive expertise in legal affairs, corporate governance, and business strategy, developed over years in

    1/14/26 7:00:00 AM ET
    $BITF
    Finance: Consumer Services
    Finance

    Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

    HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a var

    11/13/25 9:15:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    Financials

    Live finance-specific insights

    View All

    Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    – Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 –  – Revuforj® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr) net revenue of $56.0 million in 4Q25, a 22% increase vs 3Q25, and $151.6 million in FY2025, resulting in Syndax collaboration revenue of $42.4 million in FY2025 – – Completed enrollment in Phase 2 IPF trial of axatilimab; topline data expected in 4Q26 – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer ther

    2/26/26 4:01:00 PM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Danaher Announces Quarterly Dividend

    WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and

    2/24/26 4:30:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

    NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, February 26, 2026. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, February 26, 2026. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the

    2/19/26 7:00:00 AM ET
    $SNDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAQ
    $AWIN
    $BITF
    $BNOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by EMCORE Corporation

    SC 13G - EMCORE CORP (0000808326) (Subject)

    11/18/24 4:55:14 PM ET
    $EMKR
    Semiconductors
    Technology

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Siyata Mobile Inc.

    SC 13G/A - Siyata Mobile Inc. (0001649009) (Subject)

    11/14/24 7:28:44 PM ET
    $SYTA
    Telecommunications Equipment
    Telecommunications